-
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
•
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps. Transaction…
-
Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals for $462 Million
•
Healthcare fund Gurnet Point Capital (GPC) and Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE: NVO), have completed the acquisition of biopharmaceutical company Paratek Pharmaceuticals (NASDAQ: PRTK) this week. The acquisition solidifies the group’s position in the market and expands their portfolio with the addition of the antibiotic Nuzyra…
